Optimal use of taxanes in metastatic breast cancer

  • Karen M King Cross Cancer Institute
  • Sasha Lupichuk Tom Baker Cancer Centre
  • Lubna Baig Tom Baker Cancer Centre and Alberta Cancer Board Guidelines Utilization Resource Unit
  • Marc Webster Tom Baker Cancer Centre
  • Sanraj Basi Cross Cancer Institute
  • Darlene Whyte Tom Baker Cancer Centre
  • Serena Rix Cross Cancer Institute


The taxanes have an increasingly important role in the treatment of breast cancer. In clinical practice, the taxanes are now standard therapy in both early stage and metastatic breast cancer. Since the 1990’s, there have been multiple randomized clinical trials to evaluate their efficacy in the treatment of metastatic breast cancer. These trials have included treatment with taxanes alone or in combination with other chemotherapeutic agents. There are pre-existing published guidelines for use of taxanes in the management of metastatic breast cancer. The mandate of the Alberta Cancer Board Provincial Breast Tumour Group Guideline Panel was to consider and adapt the recommendations of the existing guidelines and to develop de novo guidelines to account for current evidence. The panel utilized the ADAPTE process which is a systematic process of guideline adaptation developed by the ADAPTE Collaboration. The recommendations formulated by the panel included the identification of taxane regimens that could be offered in anthracycline-naïve patients, anthracycline-pretreated/resistant patients, and patients overexpressing HER2. Potential toxicities and benefit in terms of time to progression, progression free survival, overall survival, and quality of life were also considered.
How to Cite
King, K. M., Lupichuk, S., Baig, L., Webster, M., Basi, S., Whyte, D., & Rix, S. (1). Optimal use of taxanes in metastatic breast cancer. Current Oncology, 16(3), 8-20. https://doi.org/10.3747/co.v16i3.377
Practice Guideline Series